Evidence mapPaperPMID 41096540Full record

ReviewInternational journal of molecular sciences2025

Pharmacological and Non-Pharmacological Interventions in Diabetes Mellitus: Effects on Epicardial Adipose Tissue.

Krzysztof Kuleta, Kamil Krauz, Jakub Żmuda, Karol Momot, Maciej Zarębiński, Izabela Poprawa, Małgorzata Wojciechowska

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Krzysztof KuletaChair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland.ORCID 0009-0006-5881-5458
Kamil KrauzChair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland.ORCID 0009-0000-3516-5663
Jakub ŻmudaChair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland.
Karol MomotChair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland.ORCID 0000-0001-8659-2948
Maciej ZarębińskiDepartment of Invasive Cardiology, Independent Public Specialist Western Hospital John Paul II, Lazarski University, Daleka 11, 05-825 Grodzisk Mazowiecki, Poland.ORCID 0000-0002-6782-3605
Izabela PoprawaDepartment of Invasive Cardiology, Independent Public Specialist Western Hospital John Paul II, Lazarski University, Daleka 11, 05-825 Grodzisk Mazowiecki, Poland.
Małgorzata WojciechowskaChair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland.ORCID 0000-0003-0995-1171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) has emerged as a significant issue for both individual patients and global health. Elevated blood glucose levels lead to complications affecting the cardiovascular system. Due to this fact and the growing population of patients with DM, it is crucial to broaden the knowledge concerning DM pathogenesis, allowing for the prevention and alleviation of organ-specific complications. Nowadays, pharmacological and non-pharmacological approaches are implicated in DM management. Epicardial adipose tissue (EAT) was indicated to modulate the impact of diabetes mellitus on the heart. Emerging evidence indicates that antidiabetic drugs can significantly influence EAT, often independently of their glucose-lowering effects, suggesting additional cardiometabolic benefits. However, not all drug classes, and even agents within the same class, exhibit identical effects on EAT, highlighting that some therapies may be preferred over others for cardiovascular benefit. Lifestyle interventions, commonly recommended to patients with DM, might also target epicardial fat. This article extensively reviews the impact of current DM treatment on EAT and depicts potential mechanisms. It also aims to identify gaps in knowledge and potential future directions. Insights from this work may guide future research and therapeutic strategies aimed at reducing cardiovascular risk in patients with DM.

Indexed as

Adipose TissueDiabetes MellitusHypoglycemic AgentsPericardiumAnimalsCardiovascular DiseasesEpicardial Adipose TissueHumansHypoglycemic Agentsanti-diabetic treatmentdiabetes mellitusepicardial adipose tissue

Identifiers

PMID41096540
PMCPMC12524264

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.